Lumiracoxib
Cox-2 inhibitor anti-inflammatory drug / From Wikipedia, the free encyclopedia
Lumiracoxib is a COX-2 selective inhibitor nonsteroidal anti-inflammatory drug.
Clinical data | |
---|---|
Trade names | Prexige |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 74-90%[1] |
Protein binding | >98%[1] |
Metabolism | Predominantly in the liver via oxidation and hydroxylation (CYP2C9)[1] |
Elimination half-life | 5-8 hours[1] |
Excretion | Urine (54%) and faeces (43%)[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H13ClFNO2 |
Molar mass | 293.72 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Its structure is different from that of other COX-2 inhibitors, such as celecoxib: lumiracoxib is an analogue of diclofenac (one chlorine substituted by fluorine, the phenylacetic acid has another methyl group in meta position), making it a member of the arylalkanoic acid class of NSAIDs; it binds to a different site on the COX-2 enzyme than do other COX-2 inhibitors; it is the only acidic coxib and has the highest COX-2 selectivity of any NSAID.[2]
It was patented in 1997 and approved for medical use in 2003.[3] It was manufactured by Novartis and is still sold in few countries, including Mexico, Ecuador and the Dominican Republic, under the trade name Prexige.[1] Lumiracoxib has been withdrawn from the market in several countries, mostly due to its potential for causing liver failure (sometimes requiring liver transplantation). It has never been approved for use in the United States.[1]